Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Warsaw
Clinical trial register · Poland

Clinical Trials in Warsaw, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2716 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:18 UTC
2716
Studies in scope
all four open statuses
1383
Recruiting now
open to new participants
510
Lead sponsors
across recruiting studies
Top sites
Warsaw 95 Lodz 81 Krakow 70 Poznan 67 Gdansk 59

Trials with a site in Warsaw

95 of 2716 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
AstraZeneca
Phase 3
1,330
Gdansk, Koszalin, Krakow, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
2026-09-15
Recruiting
AstraZeneca
Phase 3
2,800
Olsztyn, Warsaw, Węgrów, Wroclaw, Żywiec
2026-09-01
Recruiting
AstraZeneca
Phase 3
1,072
Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Ossy, Warsaw
2026-08-31
Recruiting
AstraZeneca
Phase 3
600
Częstochowa, Gdynia, Katowice, Lodz, Lublin, Warsaw
2026-08-12
Recruiting
AstraZeneca
Phase 3
600
Bialystok, Częstochowa, Kielce, Krakow, Lodz, Poznan, Radom, Warsaw
2026-07-08
Recruiting
AstraZeneca
Phase 3
2,000
Bialystok, Częstochowa, Kielce, Lodz, Lublin, Poznan, Radom, Warsaw
2026-07-06
Recruiting
AstraZeneca
Phase 3
1,200
Bialystok, Krakow, Lodz, Lublin, Poznan, Radom, Warsaw
2026-07-06
Recruiting
Ravulizumab Outcomes in Polish Patients With aHUS
NCT07399730Atypical Hemolytic Uremic Syndrome
AstraZeneca
Observational
80
Gdansk, Katowice, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2026-06-24
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bialystok, Krakow, Lodz, Poznan, Rzeszów, Warsaw
2026-06-11
Recruiting
AstraZeneca
Phase 2
80
Bydgoszcz, Krakow, Lodz, Lublin, Warsaw
2026-06-04
Recruiting
AstraZeneca
Observational
2,150
Lublin, Krakow, Radom, Bialystok, Częstochowa, Poznan, Warsaw, Lodz
2026-05-06
Recruiting
AstraZeneca
Phase 3
670
Gdansk, Krakow, Warsaw
2026-05-04
Recruiting
AstraZeneca
Phase 3
508
Gdansk, Gliwice, Lublin, Poznan, Warsaw, Wroclaw
2026-02-23
Recruiting
AstraZeneca
Phase 3
2,130
Gdansk, Koszalin, Krakow, Lublin, Olsztyn, Warsaw
2026-02-03
Recruiting
AstraZeneca
Phase 2
320
Krakow, Torun, Warsaw, Wroclaw
2025-12-15
Recruiting
AstraZeneca
Phase 2
230
Lublin, Warsaw
2025-12-10
Recruiting
AstraZeneca
Phase 3
1,100
Koszalin, Krakow, Lodz, Olsztyn, Warsaw
2025-12-04
Recruiting
AstraZeneca
Phase 3
400
Lodz, Olsztyn, Poznan, Warsaw
2025-10-31
Recruiting
AstraZeneca
Phase 3
700
Gdynia, Gliwice, Koszalin, Krakow, Piotrkow Trybunalski, Poznan, Rzeszów, Warsaw
2025-08-06
Recruiting
AstraZeneca
Phase 3
1,220
Bydgoszcz, Gdansk, Koszalin, Lublin, Olsztyn, Warsaw
2025-05-06
Recruiting
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
AstraZeneca
Phase 3
14
Kielce, Warsaw
2025-04-17
Recruiting
AstraZeneca
Phase 3
840
Bialystok, Gdansk, Koszalin, Lodz, Olsztyn, Przemyśl, Tomaszów Mazowiecki, Warsaw
2025-03-01
Active, closed
AstraZeneca
Phase 2
24
Warsaw
2024-12-11
Recruiting
AstraZeneca
Phase 3
1,160
Bialystok, Biała Podlaska, Bydgoszcz, Bystra, Lodz, Lublin, Poznan, Warsaw
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Bialystok, Biała Podlaska, Bydgoszcz, Bystra, Lodz, Lublin, Poznan, Warsaw
2024-11-18
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2
120
Bydgoszcz, Chojnice, Krakow, Lublin, Poznan, Sopot, Warsaw, Wroclaw
2024-08-28
Recruiting
AstraZeneca
Phase 3
620
Bialystok, Katowice, Krakow, Lublin, Warsaw, Wroclaw
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
Gdansk, Gliwice, Katowice, Krakow, Lublin, Warsaw, Wroclaw
2024-08-07
Active, closed
AstraZeneca
Phase 3
339
Katowice, Kielce, Ossy, Rzeszów, Warsaw
2024-06-29
Recruiting
AstraZeneca
Phase 3
582
Bystra, Olsztyn, Poznan, Warsaw
2024-04-29
Recruiting
AstraZeneca
Phase 3
100
Lodź, Warsaw, Wroclaw
2024-03-14
Active, closed
AstraZeneca
Phase 3
594
Bielsko-Biala, Gdansk, Katowice, Krakow, Lublin, Słupsk, Warsaw
2024-03-04
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 2
226
Krakow, Warsaw
2023-12-13
Active, closed
AstraZeneca
Phase 2
108
Gdynia, Krakow, Warsaw
2023-12-13
Active, closed
AstraZeneca
Phase 3
760
Bydgoszcz, Krakow, Lublin, Przemyśl, Warsaw
2023-12-04
Active, closed
AstraZeneca
Phase 3
1,898
Bydgoszcz, Koszalin, Poznan, Rzeszów, Warsaw, Wroclaw
2023-11-21
Active, closed
AstraZeneca
Phase 3
1,902
Bialystok, Bydgoszcz, Gdynia, Krakow, Lodz, Warsaw
2023-11-14
Active, closed
AstraZeneca
Phase 3
863
Bystra, Olsztyn, Poznan, Warsaw
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
Bydgoszcz, Krakow, Lodz, Sosnowiec, Warsaw
2023-11-08
Active, closed
AstraZeneca
Phase 3
1,835
Chrzanów, Krakow, Lodz, Poznan, Radom, Rzeszów, Szczecin, Warsaw
2023-11-07
Active, closed
AstraZeneca
Phase 3
895
Lublin, Poznan, Przemyśl, Radom, Warsaw
2023-10-24
Recruiting
AstraZeneca
Phase 3
800
Bialystok, Gdansk, Gliwice, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2023-09-22
Recruiting
AstraZeneca
Phase 3
3,527
Chrzanów, Lodz, Rzeszów, Warsaw, Wroclaw, Łańcut, Łęczna
2022-12-13
Recruiting
AstraZeneca
Phase 2
454
Gliwice, Krakow, Lodz, Poznan, Warsaw
2022-09-06
Active, closed
AstraZeneca
Phase 2
194
Brzozów, Gdansk, Krakow, Lodz, Poznan, Warsaw
2022-08-11
By invitation
AstraZeneca
Phase 3
214
Bialystok, Bydgoszcz, Elblag, Lodz, Olsztyn, Szczecin, Warsaw
2022-04-19
Active, closed
AstraZeneca
Phase 3
390
Poznan, Warsaw
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Bialystok, Gliwice, Katowice, Lodz, Warsaw, Wroclaw
2022-02-18
Active, closed
AstraZeneca
Phase 3
1,051
Bydgoszcz, Gdansk, Koszalin, Poznan, Siedlce, Tomaszów Mazowiecki, Warsaw
2022-02-07
Active, closed
AstraZeneca
Phase 3
454
Gdansk, Olsztyn, Przemyśl, Warsaw
2021-10-28
Active, closed
AstraZeneca
Phase 3
927
Bialystok, Biała Podlaska, Bydgoszcz, Koszalin, Lublin, Rzeszów, Warsaw
2021-10-25
Recruiting
AstraZeneca
Phase 1/2
460
Gdansk, Warsaw
2021-10-18
Active, closed
AstraZeneca
Phase 3
315
Bydgoszcz, Gdynia, Koszalin, Lodz, Poznan, Rzeszów, Tomaszów Mazowiecki, Warsaw
2021-06-30
Active, closed
AstraZeneca
Phase 3
506
Gdansk, Krakow, Opole, Warsaw
2021-06-22
Active, closed
AstraZeneca
Phase 3
367
Katowice, Kościan, Krakow, Lodz, Lublin, Nowa Sól, Ustroń, Warsaw
2021-06-08
Active, closed
AstraZeneca
Phase 3
893
Bydgoszcz, Krakow, Warsaw
2021-05-10
Recruiting
AstraZeneca
Phase 1
304
Gdansk, Krakow, Olsztyn, Tomaszów Mazowiecki, Warsaw
2021-03-09
Active, closed
AstraZeneca
Phase 1
155
Gdansk, Lodz, Lublin, Warsaw
2021-02-02
Active, closed
AstraZeneca
Phase 3
957
Bialystok, Gdansk, Krakow, Lodz, Poznan, Warsaw
2020-11-17
Active, closed
AstraZeneca
Phase 1/2
702
Bydgoszcz, Gdansk, Gdynia, Grzepnica, Lodz, Torun, Warsaw
2020-11-12
Active, closed
AstraZeneca
Phase 3
640
Katowice, Krakow, Lodz, Siedlce, Warsaw
2020-10-19
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca
Phase 2
477
Bydgoszcz, Gdansk, Krakow, Poznan, Warsaw
2020-08-18
Active, closed
AstraZeneca
Phase 3
866
Bydgoszcz, Koszalin, Krakow, Lodz, Rzeszów, Warsaw, Wroclaw
2020-07-24
Active, closed
AstraZeneca
Phase 2
452
Gdansk, Konin, Koszalin, Krakow, Warsaw
2020-06-03
Active, closed
AstraZeneca
Phase 2
240
Bydgoszcz, Lodz, Piła, Rzeszów, Skorzewo, Warsaw
2020-04-22
Active, closed
AstraZeneca
Phase 3
818
Bydgoszcz, Krakow, Olsztyn, Warsaw
2020-04-16
Active, closed
AstraZeneca
Phase 3
923
Bydgoszcz, Konin, Poznan, Racibórz, Radom, Tomaszów Mazowiecki, Warsaw, Wroclaw
2019-06-25
Active, closed
AstraZeneca
Phase 3
810
Gdansk, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
2019-04-16
Recruiting
AstraZeneca
Phase 3
140
Bialystok, Krakow, Lodz, Warsaw
2019-04-02
Active, closed
AstraZeneca
Phase 1
175
Bialystok, Bydgoszcz, Gdansk, Grudziądz, Lodz, Olsztyn, Tomaszów Mazowiecki, Warsaw
2018-12-27
Active, closed
AstraZeneca
Phase 1/2
243
Gdansk, Krakow, Lublin, Opole, Rzeszów, Warsaw
2018-12-21
Active, closed
AstraZeneca
Phase 3
825
Bialystok, Olsztyn, Warsaw
2018-12-06
Active, closed
AstraZeneca
Phase 3
407
Bialystok, Gdansk, Poznan, Tomaszów Mazowiecki, Warsaw
2018-11-27
Active, closed
AstraZeneca
Phase 3
730
Gdansk, Olsztyn, Poznan, Tomaszów Mazowiecki, Warsaw, Wroclaw
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,018
Bialystok, Gdansk, Grudziądz, Koszalin, Piotrkow Trybunalski, Poznan, Warsaw, Wroclaw
2018-05-14
Active, closed
AstraZeneca
Phase 3
1,186
Olsztyn, Tomaszów Mazowiecki, Warsaw, Wodzisław Śląski
2017-06-01
Active, closed
AstraZeneca
Phase 3
987
Bialystok, Lublin, Olsztyn, Warsaw
2017-03-27
Active, closed
AstraZeneca
Phase 3
669
Bialystok, Grudziądz, Koszalin, Lublin, Mrozy, Warsaw, Wroclaw
2017-01-02
Active, closed
AstraZeneca
Phase 3
953
Bydgoszcz, Kielce, Krakow, Lodz, Mrozy, Olsztyn, Poznan, Warsaw
2015-11-03
Active, closed
AstraZeneca
Phase 3
1,126
Gdansk, Gdynia, Gliwice, Olsztyn, Otwock, Szczecin, Warsaw
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Krakow, Lodz, Otwock, Poznan, Racibórz, Warsaw, Wieliszew
2015-10-21
Active, closed
AstraZeneca
Phase 1
344
Gdansk, Krakow, Olsztyn, Poznan, Warsaw
2014-08-05
Active, closed
AstraZeneca
Phase 3
1,837
Gdansk, Grzepnica, Lodz, Olsztyn, Poznan, Warsaw
2014-04-22
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
AstraZeneca
Phase 3
327
Grzepnica, Olsztyn, Warsaw
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
AstraZeneca
Phase 3
450
Grzepnica, Olsztyn, Warsaw
2013-08-26
Rows per page Showing 1–95 of 95
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 November 2026. https://priyalifescience.com/clinical-trials-poland/city/warsaw

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,716 studies in total at the last sync on 15 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 95 of those studies with a site in Warsaw that also match the filters currently applied.

How many clinical trials are recruiting in Warsaw?

39 of the 95 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 55 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Warsaw), 95 studies
PhaseStudiesRecruitingShare
Phase 3712874.7%
Phase 214714.7%
Phase 1515.3%
Phase 1/2313.2%
Observational222.1%

Most active sponsors

Lead sponsors with the most studies (Warsaw)
Lead sponsorStudiesRecruiting
AstraZeneca9539
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.